Birchview Capital, LP
Known title: 10% OwnerCIK: 0001618205
Birchview Capital, LP's purchase track record
How the stock did after each of Birchview Capital, LP's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since May 11, 2022
Stock higher 6 months later
67%
3 months: 100%
Median 6-month return
+9.3%
3 months: +10.6%
Beat the S&P 500
33%
median -0.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/23/2023 | ELUT | $207K | +86.4% | +9.3% | +9.7% |
| 12/1/2022 | ELUT | $397K | +0.7% | -48.0% | +3.5% |
| 5/11/2022 | ELUT | $1K | +10.6% | +38.9% | -4.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ELUT | ▲ Buy | Open Market | 10,000 | $16K | 3/27/2023 | View on chart |
| ELUT | ▲ Buy | Open Market | 18,000 | $24K | 3/24/2023 | View on chart |
| ELUT | ▲ Buy | Open Market | 2,000 | $3K | 3/24/2023 | View on chart |
| ELUT | ▲ Buy | Open Market | 10,000 | $15K | 3/23/2023 | View on chart |
| ELUT | ▲ Buy | Open Market | 100,000 | $149K | 3/23/2023 | View on chart |
| ELUT | ▲ Buy | Open Market | 9,061 | $34K | 12/8/2022 | View on chart |
| ELUT | ▲ Buy | Open Market | 4,000 | $15K | 12/8/2022 | View on chart |
| ELUT | ▲ Buy | Open Market | 10,000 | $36K | 12/7/2022 | View on chart |
| ELUT | ▲ Buy | Open Market | 34,000 | $122K | 12/7/2022 | View on chart |
| ELUT | ▲ Buy | Open Market | 40,000 | $190K | 12/1/2022 | View on chart |
| ELUT | ▲ Buy | Open Market | 200 | $1K | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.